A new study from Japan is raising hopes for a needle-free approach to diabetes management through the development of an oral insulin pill.

Researchers at Kumamoto University have created a peptide-based delivery system known as DNP-V, which has shown encouraging results in tests on diabetic mice.

The study, published in the journal *Molecular Pharmaceutics*, suggests that this method could one day replace injections for insulin delivery.

For people with diabetes, daily insulin injections are often a constant and difficult part of life.

Here's What They're Not Telling You About Your Retirement

Associate professor Shingo Ito, a researcher on the project, said in a press release, “Insulin injections remain a daily burden for many patients. Our peptide-based platform offers a new route to deliver insulin orally, and may be applicable to long-acting insulin formulations and other injectable biologics.”

The team aimed to address one of the biggest challenges in diabetes treatment: delivering insulin effectively by mouth, since protein absorption in the intestines is typically poor. Their approach uses DNP-V peptides to move the insulin through the small intestine, where it can be absorbed more efficiently.

In laboratory trials, researchers combined DNP-V with zinc-stabilized insulin to increase its stability.

The result was rapid and sustained drops in blood glucose levels in the mice, effectively bringing them close to normal blood sugar ranges.

This Could Be the Most Important Video Gun Owners Watch All Year

The study also found that when DNP-V was directly attached to insulin, intestinal absorption improved even further. This combination reduced blood sugar spikes after meals with only one daily dose in several diabetic mouse models.

According to the research team, their results indicate that DNP peptides could serve as flexible carriers for oral versions of large-molecule drugs, including insulin.

They wrote, “This technology can simply and effectively convert injectable biopharmaceuticals into orally administrable forms, offering a promising path to practical, patient-friendly oral therapies.”

However, the researchers also noted that the trials were conducted only in animals, and outcomes in humans remain uncertain. More extensive testing will be required to determine if the treatment works safely and effectively in people.

Medical experts not involved in the study say the findings are exciting but caution that human results are not yet known. Dr. Marc Siegel said that oral insulin could offer notable benefits if proven effective.

“Insulin use, especially in type 1 diabetes, is sometimes difficult to regulate by injection,” he explained. “Oral use would have major advantages. This is very promising provided that it works in humans, which is a big ‘if.’”

Dr. Philip Rabito, an endocrinologist and weight-loss specialist in New York City, called the peptide “a promising step toward clinically viable oral insulin.” He said, “If these findings are confirmed in humans, the approach could reduce injection burden, improve adherence, and potentially help lower complication risk in patients with type 1 diabetes and insulin-requiring type 2 diabetes.”

Another endocrinologist, Dr. Peter Balazs, emphasized that the research is still in an early phase. He told Fox News Digital that while oral insulin might make management easier, it would not replace all insulin injections for type 1 diabetes, since basal insulin would still be necessary.

Balazs added that patients should not view this as a cure. The focus, he said, remains on improving insulin delivery systems rather than restoring natural insulin production in the pancreas. He also noted that oral insulin dosing may vary day to day compared to injections.

For now, the potential pill remains under investigation. Yet the possibility of replacing daily needles with a simple tablet marks an encouraging development in the ongoing effort to make diabetes care more comfortable and effective.